Loading...

Ryusuke Hatae, MD, PhD

Title(s)Postdoctoral Scholar, Neurological Surgery
SchoolSchool of Medicine
Address1450 Third St
San Francisco CA 94158
Phone415-476-1637
ORCID ORCID Icon0000-0001-5636-8064 Additional info
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Current trend in treatment of glioblastoma in Japan: a national survey using the diagnostic procedure combination database (J-ASPECT study-glioblastoma). Int J Clin Oncol. 2021 May 11. Funakoshi Y, Hata N, Kuga D, Hatae R, Sangatsuda Y, Fujioka Y, Takigawa K, Yoshimoto K, Mizoguchi M, Iihara K. PMID: 33974184.
      View in: PubMed   Mentions:    Fields:    
    2. Clinical significance of CDKN2A homozygous deletion in combination with methylated MGMT status for IDH-wildtype glioblastoma. Cancer Med. 2021 Apr 10. Funakoshi Y, Hata N, Takigawa K, Arita H, Kuga D, Hatae R, Sangatsuda Y, Fujioka Y, Sako A, Umehara T, Yoshitake T, Togao O, Hiwatashi A, Yoshimoto K, Iwaki T, Mizoguchi M. PMID: 33838014.
      View in: PubMed   Mentions:    Fields:    
    3. Pediatric Glioma: An Update of Diagnosis, Biology, and Treatment. Cancers (Basel). 2021 Feb 12; 13(4). Funakoshi Y, Hata N, Kuga D, Hatae R, Sangatsuda Y, Fujioka Y, Takigawa K, Mizoguchi M. PMID: 33673070.
      View in: PubMed   Mentions:
    4. Molecular diagnosis of diffuse glioma using a chip-based digital PCR system to analyze IDH, TERT, and H3 mutations in the cerebrospinal fluid. J Neurooncol. 2021 Jan 08. Fujioka Y, Hata N, Akagi Y, Kuga D, Hatae R, Sangatsuda Y, Michiwaki Y, Amemiya T, Takigawa K, Funakoshi Y, Sako A, Iwaki T, Iihara K, Mizoguchi M. PMID: 33417137.
      View in: PubMed   Mentions: 2     Fields:    
    5. Mesenchymal glioblastoma-induced mature de-novo vessel formation of vascular endothelial cells in a microfluidic device. Mol Biol Rep. 2021 Jan 02. Amemiya T, Hata N, Mizoguchi M, Yokokawa R, Kawamura Y, Hatae R, Sangatsuda Y, Kuga D, Fujioka Y, Takigawa K, Akagi Y, Yoshimoto K, Iihara K, Miura T. PMID: 33387197.
      View in: PubMed   Mentions:    Fields:    
    6. Update on Chemotherapeutic Approaches and Management of Bevacizumab Usage for Glioblastoma. Pharmaceuticals (Basel). 2020 Dec 16; 13(12). Funakoshi Y, Hata N, Kuga D, Hatae R, Sangatsuda Y, Fujioka Y, Takigawa K, Mizoguchi M. PMID: 33339404.
      View in: PubMed   Mentions:
    7. TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutations. Acta Neuropathol Commun. 2020 11 23; 8(1):201. Arita H, Matsushita Y, Machida R, Yamasaki K, Hata N, Ohno M, Yamaguchi S, Sasayama T, Tanaka S, Higuchi F, Iuchi T, Saito K, Kanamori M, Matsuda KI, Miyake Y, Tamura K, Tamai S, Nakamura T, Uda T, Okita Y, Fukai J, Sakamoto D, Hattori Y, Pareira ES, Hatae R, Ishi Y, Miyakita Y, Tanaka K, Takayanagi S, Otani R, Sakaida T, Kobayashi K, Saito R, Kurozumi K, Shofuda T, Nonaka M, Suzuki H, Shibuya M, Komori T, Sasaki H, Mizoguchi M, Kishima H, Nakada M, Sonoda Y, Tominaga T, Nagane M, Nishikawa R, Kanemura Y, Kuchiba A, Narita Y, Ichimura K. PMID: 33228806.
      View in: PubMed   Mentions: 1     Fields:    
    8. Base-resolution methylomes of gliomas bearing histone H3.3 mutations reveal a G34 mutant-specific signature shared with bone tumors. Sci Rep. 2020 09 30; 10(1):16162. Sangatsuda Y, Miura F, Araki H, Mizoguchi M, Hata N, Kuga D, Hatae R, Akagi Y, Amemiya T, Fujioka Y, Arai Y, Yoshida A, Shibata T, Yoshimoto K, Iihara K, Ito T. PMID: 32999376.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    9. First-line bevacizumab contributes to survival improvement in glioblastoma patients complementary to temozolomide. J Neurooncol. 2020 Feb; 146(3):451-458. Hata N, Mizoguchi M, Kuga D, Hatae R, Akagi Y, Sangatsuda Y, Amemiya T, Michiwaki Y, Fujioka Y, Takigawa K, Suzuki SO, Yoshitake T, Togao O, Hiwatashi A, Yoshimoto K, Iihara K. PMID: 32020475.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    10. Combination of host immune metabolic biomarkers for the PD-1 blockade cancer immunotherapy. JCI Insight. 2020 01 30; 5(2). Hatae R, Chamoto K, Kim YH, Sonomura K, Taneishi K, Kawaguchi S, Yoshida H, Ozasa H, Sakamori Y, Akrami M, Fagarasan S, Masuda I, Okuno Y, Matsuda F, Hirai T, Honjo T. PMID: 31855576.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    11. Current issues and perspectives in PD-1 blockade cancer immunotherapy. Int J Clin Oncol. 2020 May; 25(5):790-800. Chamoto K, Hatae R, Honjo T. PMID: 31900651.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    12. A case of diffuse midline glioma, H3 K27M mutant mimicking a hemispheric malignant glioma in an elderly patient. Neuropathology. 2020 Feb; 40(1):99-103. Fujioka Y, Hata N, Hatae R, Suzuki SO, Sangatsuda Y, Nakahara Y, Mizoguchi M, Iihara K. PMID: 31762138.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    13. Relevance of calcification and contrast enhancement pattern for molecular diagnosis and survival prediction of gliomas based on the 2016 World Health Organization Classification. Clin Neurol Neurosurg. 2019 Dec; 187:105556. Michiwaki Y, Hata N, Mizoguchi M, Hiwatashi A, Kuga D, Hatae R, Akagi Y, Amemiya T, Fujioka Y, Togao O, Suzuki SO, Yoshimoto K, Iwaki T, Iihara K. PMID: 31639630.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    14. Analytical performance of a new automated chemiluminescent magnetic immunoassays for soluble PD-1, PD-L1, and CTLA-4 in human plasma. Sci Rep. 2019 07 12; 9(1):10144. Goto M, Chamoto K, Higuchi K, Yamashita S, Noda K, Iino T, Miura M, Yamasaki T, Ogawa O, Sonobe M, Date H, Hamanishi J, Mandai M, Tanaka Y, Chikuma S, Hatae R, Muto M, Minamiguchi S, Minato N, Honjo T. PMID: 31300681.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    15. Gliosarcoma arising from oligodendroglioma (Oligosarcoma): A case report with genetic analyses. Pathol Int. 2018 Oct; 68(10):567-573. Tanaka S, Hitotsumatsu T, Sugita Y, Ishido K, Ito O, Hatae R, Akagi Y, Yoshimoto K, Iihara K. PMID: 30246385.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    16. An elderly case of malignant small cell glioma with hemorrhage coexistent with a calcified pilocytic astrocytoma component in the cerebellar hemisphere. Neuropathology. 2018 Oct; 38(5):493-497. Sangatsuda Y, Hata N, Suzuki SO, Akagi Y, Hatae R, Kuga D, Yoshimoto K, Momosaki S, Iwaki T, Iihara K. PMID: 29851180.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    17. Reclassification of 400 consecutive glioma cases based on the revised 2016WHO classification. Brain Tumor Pathol. 2018 Apr; 35(2):81-89. Akagi Y, Yoshimoto K, Hata N, Kuga D, Hatae R, Amemiya T, Sangatsuda Y, Suzuki SO, Iwaki T, Mizoguchi M, Iihara K. PMID: 29569163.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    18. The Effectiveness of Salvage Treatments for Recurrent Lesions of Oligodendrogliomas Previously Treated with Upfront Chemotherapy. World Neurosurg. 2018 Jun; 114:e735-e742. Kuga D, Hata N, Akagi Y, Amemiya T, Sangatsuda Y, Hatae R, Yoshimoto K, Mizoguchi M, Iihara K. PMID: 29551724.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    19. High-resolution melting and immunohistochemical analysis efficiently detects mutually exclusive genetic alterations of adamantinomatous and papillary craniopharyngiomas. Neuropathology. 2018 Feb; 38(1):3-10. Yoshimoto K, Hatae R, Suzuki SO, Hata N, Kuga D, Akagi Y, Amemiya T, Sangatsuda Y, Mukae N, Mizoguchi M, Iwaki T, Iihara K. PMID: 28840946.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    20. Prevalence and clinicopathological features of H3.3 G34-mutant high-grade gliomas: a retrospective study of 411 consecutive glioma cases in a single institution. Brain Tumor Pathol. 2017 Jul; 34(3):103-112. Yoshimoto K, Hatae R, Sangatsuda Y, Suzuki SO, Hata N, Akagi Y, Kuga D, Hideki M, Yamashita K, Togao O, Hiwatashi A, Iwaki T, Mizoguchi M, Iihara K. PMID: 28447171.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    21. Insular primary glioblastomas with IDH mutations: Clinical and biological specificities. Neuropathology. 2017 Jun; 37(3):200-206. Hata N, Hatae R, Yoshimoto K, Murata H, Kuga D, Akagi Y, Sangatsuda Y, Suzuki SO, Iwaki T, Mizoguchi M, Iihara K. PMID: 28116838.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    22. Add-on bevacizumab can prevent early clinical deterioration and prolong survival in newly diagnosed partially resected glioblastoma patients with a poor performance status. Onco Targets Ther. 2017; 10:429-437. Hata N, Yoshimoto K, Hatae R, Kuga D, Akagi Y, Sangatsuda Y, Suzuki SO, Shono T, Mizoguchi M, Iihara K. PMID: 28176936.
      View in: PubMed   Mentions:
    23. Deferred radiotherapy and upfront procarbazine-ACNU-vincristine administration for 1p19q codeleted oligodendroglial tumors are associated with favorable outcome without compromising patient performance, regardless of WHO grade. Onco Targets Ther. 2016; 9:7123-7131. Hata N, Yoshimoto K, Hatae R, Kuga D, Akagi Y, Suzuki SO, Iwaki T, Shono T, Mizoguchi M, Iihara K. PMID: 27895504.
      View in: PubMed   Mentions:
    24. [Rapid Progression in Early-Stage Primary Glioblastoma Multiforme:A Case Report]. No Shinkei Geka. 2016 Nov; 44(11):945-950. Maehara N, Amano T, Haga S, Makihara K, Shimogawa T, Hatae R, Yoshimoto K, Suzuki S, Morioka T, Iihara K. PMID: 27832617.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    25. A comprehensive analysis identifies BRAF hotspot mutations associated with gliomas with peculiar epithelial morphology. Neuropathology. 2017 Jun; 37(3):191-199. Hatae R, Hata N, Suzuki SO, Yoshimoto K, Kuga D, Murata H, Akagi Y, Sangatsuda Y, Iwaki T, Mizoguchi M, Iihara K. PMID: 27792249.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    26. Current Trends and Healthcare Resource Usage in the Hospital Treatment of Primary Malignant Brain Tumor in Japan: A National Survey Using the Diagnostic Procedure Combination Database (J-ASPECT Study-Brain Tumor). Neurol Med Chir (Tokyo). 2016 Nov 15; 56(11):664-673. Yoshimoto K, Kada A, Kuga D, Hatae R, Murata H, Akagi Y, Nishimura K, Kurogi R, Nishimura A, Hata N, Mizoguchi M, Sayama T, Iihara K. PMID: 27680329.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    27. Precise Detection of IDH1/2 and BRAF Hotspot Mutations in Clinical Glioma Tissues by a Differential Calculus Analysis of High-Resolution Melting Data. PLoS One. 2016; 11(8):e0160489. Hatae R, Hata N, Yoshimoto K, Kuga D, Akagi Y, Murata H, Suzuki SO, Mizoguchi M, Iihara K. PMID: 27529619.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    28. A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas. Acta Neuropathol Commun. 2016 08 08; 4(1):79. Arita H, Yamasaki K, Matsushita Y, Nakamura T, Shimokawa A, Takami H, Tanaka S, Mukasa A, Shirahata M, Shimizu S, Suzuki K, Saito K, Kobayashi K, Higuchi F, Uzuka T, Otani R, Tamura K, Sumita K, Ohno M, Miyakita Y, Kagawa N, Hashimoto N, Hatae R, Yoshimoto K, Shinojima N, Nakamura H, Kanemura Y, Okita Y, Kinoshita M, Ishibashi K, Shofuda T, Kodama Y, Mori K, Tomogane Y, Fukai J, Fujita K, Terakawa Y, Tsuyuguchi N, Moriuchi S, Nonaka M, Suzuki H, Shibuya M, Maehara T, Saito N, Nagane M, Kawahara N, Ueki K, Yoshimine T, Miyaoka E, Nishikawa R, Komori T, Narita Y, Ichimura K. PMID: 27503138.
      View in: PubMed   Mentions: 53     Fields:    Translation:HumansCells
    29. Immune checkpoint inhibitors targeting programmed cell death-1 (PD-1) in cancer therapy. Rinsho Ketsueki. 2016; 57(10):2224-2231. Hatae R, Chamoto K. PMID: 27795534.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimals
    30. Detection of proneural/mesenchymal marker expression in glioblastoma: temporospatial dynamics and association with chromatin-modifying gene expression. J Neurooncol. 2015 Oct; 125(1):33-41. Murata H, Yoshimoto K, Hatae R, Akagi Y, Mizoguchi M, Hata N, Kuga D, Nakamizo A, Amano T, Sayama T, Iihara K. PMID: 26272600.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    31. Genetic analysis of a case of glioblastoma with oligodendroglial component arising during the progression of diffuse astrocytoma. Pathol Oncol Res. 2015 Jul; 21(3):839-43. Hata N, Suzuki SO, Murata H, Hatae R, Akagi Y, Sangatsuda Y, Amano T, Yoshimoto K, Tahira T, Mizoguchi M. PMID: 25354913.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    32. Trochlear nerve schwannoma with intratumoral hemorrhage presenting with persistent hiccups: a case report. J Neurol Surg Rep. 2014 Aug; 75(1):e183-8. Hatae R, Miyazono M, Kohri R, Maeda K, Naito S. PMID: 25083382.
      View in: PubMed   Mentions:
    33. [Two cases of anterior cerebral artery aneurysm associated with accessory anterior cerebral artery: review of the literature and points of diagnosis]. No Shinkei Geka. 2014 May; 42(5):461-6. Maeda K, Tanaka S, Hatae R, Maeda Y, Miyazono M. PMID: 24807551.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    34. A rare case of Chiari type-1 malformation accompanied by symptomatic cerebrospinal fluid hypovolemia: comparison of congenital Chiari type-1 malformation and acquired Chiari malformation secondary to cerebrospinal fluid hypovolemia: case report. Neurol Med Chir (Tokyo). 2014; 54(7):558-62. Hatae R, Kohri R, Maeda K, Miyazono M. PMID: 24477061.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    35. Complex DNA repair pathways as possible therapeutic targets to overcome temozolomide resistance in glioblastoma. Front Oncol. 2012; 2:186. Yoshimoto K, Mizoguchi M, Hata N, Murata H, Hatae R, Amano T, Nakamizo A, Sasaki T. PMID: 23227453.
      View in: PubMed   Mentions:
    36. [A case of internal carotid artery stenosis with discontinuance of carotid endarterectomy due to the tight adhesions around the internal carotid artery]. No Shinkei Geka. 2012 May; 40(5):445-50. Kohri R, Miyazono M, Hatae R, Maeda K, Takahira A, Maeda Y, Mizota T, Naito S. PMID: 22538287.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    Ryusuke's Networks
    Concepts (141)
    Derived automatically from this person's publications.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _
    ↑